

Oscar Krijgsman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7576059/publications.pdf>

Version: 2024-02-01

38
papers

4,875
citations

279798

23
h-index

330143

37
g-index

41
all docs

41
docs citations

41
times ranked

9653
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasticity of Extrachromosomal and Intrachromosomal <i>BRAF</i> Amplifications in Overcoming Targeted Therapy Dosage Challenges. <i>Cancer Discovery</i> , 2022, 12, 1046-1069.	9.4	27
2	Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade. <i>Cancer Research</i> , 2021, 81, 1775-1787.	0.9	25
3	High CD8 + tumour-infiltrating lymphocyte density associates with unfavourable prognosis in oesophageal adenocarcinoma following poor response to neoadjuvant chemoradiotherapy. <i>Histopathology</i> , 2021, 79, 238-251.	2.9	4
4	Comprehensive analysis of cutaneous and uveal melanoma liver metastases. , 2020, 8, e001501.		40
5	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. <i>Nature Communications</i> , 2020, 11, 3946.	12.8	71
6	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	27.8	1,421
7	Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. <i>Cell</i> , 2019, 178, 585-599.e15.	28.9	162
8	Clonality analysis of pulmonary tumors by genome-wide copy number profiling. <i>PLoS ONE</i> , 2019, 14, e0223827.	2.5	9
9	Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFN γ signaling in non-small cell lung cancer. <i>PLoS ONE</i> , 2019, 14, e0216864.	2.5	11
10	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 948-960.	10.7	346
11	Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. <i>Nature Cell Biology</i> , 2019, 21, 778-790.	10.3	24
12	Frequent clonal relations between metastases and non-index prostate cancer lesions. <i>JCI Insight</i> , 2019, 4, .	5.0	27
13	Targeting <i>CDK2</i> overcomes melanoma resistance against <i>BRAF</i> and Hsp90 inhibitors. <i>Molecular Systems Biology</i> , 2018, 14, e7858.	7.2	53
14	Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. <i>Nature Medicine</i> , 2018, 24, 203-212.	30.7	178
15	Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. <i>Nature Medicine</i> , 2018, 24, 1655-1661.	30.7	599
16	XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data. <i>BMC Bioinformatics</i> , 2018, 19, 366.	2.6	94
17	BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. <i>Cell Reports</i> , 2016, 16, 263-277.	6.4	61
18	Genomic profiling of stage II and III colon cancers reveals <i>APC</i> mutations to be associated with survival in stage III colon cancer patients. <i>Oncotarget</i> , 2016, 7, 73876-73887.	1.8	9

#	ARTICLE	IF	CITATIONS
19	miR-129-3p controls centrosome number in metastatic prostate cancer cells by repressing CP110. <i>Oncotarget</i> , 2016, 7, 16676-16687.	1.8	20
20	Immortalization capacity of HPV types is inversely related to chromosomal instability. <i>Oncotarget</i> , 2016, 7, 37608-37621.	1.8	25
21	Neoadjuvant tamoxifen synchronizes ER \pm binding and gene expression profiles related to outcome and proliferation. <i>Oncotarget</i> , 2016, 7, 33901-33918.	1.8	13
22	Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. <i>EMBO Molecular Medicine</i> , 2015, 7, 1104-1118.	6.9	129
23	Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms. <i>Molecular Oncology</i> , 2015, 9, 1274-1286.	4.6	29
24	Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13308-13311.	7.1	356
25	High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0138141.	2.5	24
26	Focal Chromosomal Copy Number Aberrations Identify CMTM8 and GPR177 as New Candidate Driver Genes in Osteosarcoma. <i>PLoS ONE</i> , 2014, 9, e115835.	2.5	34
27	FocalCall: An R Package for the Annotation of Focal Copy Number Aberrations. <i>Cancer Informatics</i> , 2014, 13, CIN.S19519.	1.9	2
28	Parallel In Vivo and In Vitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition. <i>Cell Reports</i> , 2014, 9, 1375-1386.	6.4	34
29	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. <i>Nature Communications</i> , 2014, 5, 5712.	12.8	503
30	Gene dosage dependent overexpression at the 13q amplicon identifies <i>DIS3</i> as candidate oncogene in colorectal cancer progression. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 339-348.	2.8	31
31	Focal aberrations indicate <i>EYA2</i> and <i>hsa-miR-375</i> as oncogene and tumor suppressor in cervical carcinogenesis. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 56-68.	2.8	76
32	Dissecting the gray zone between follicular lymphoma and marginal zone lymphoma using morphological and genetic features. <i>Haematologica</i> , 2013, 98, 1921-1929.	3.5	13
33	High-Risk Human Papillomavirus-Positive Lung Cancer: Molecular Evidence for a Pattern of Pulmonary Metastasis. <i>Journal of Thoracic Oncology</i> , 2013, 8, 711-718.	1.1	39
34	A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 37-47.	2.5	121
35	CGH arrays compared for DNA isolated from formalin-fixed, paraffin-embedded material. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 344-352.	2.8	33
36	TSPYL5 suppresses p53 levels and function by physical interaction with USP7. <i>Nature Cell Biology</i> , 2011, 13, 102-108.	10.3	105

#	ARTICLE	IF	CITATIONS
37	Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer. <i>International Journal of Molecular Medicine</i> , 2010, 26, 837-43.	4.0	21
38	Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7003-7011.	7.0	87